SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TRDA reported Third Quarter 2026 results. The price and volatility reaction is pending.
TRDAearnings

Earnings reactions, page 6

Entrada Therapeutics, Inc. (TRDA) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Collaboration revenue was $0.9 million for the third quarter of 2026, compared to $1.6 million for the same period in 2025.
  • Research & Development (R&D) expenses were $32.4 million for the third quarter of 2026, compared to $38.4 million for the same period in 2025.
  • General & Administrative (G&A) expenses were $10.2 million for the third quarter of 2026, compared to $10.3 million for the same period in 2025.
  • Net loss was $39.7 million for the third quarter of 2026, compared to $44.1 million for the same period in 2025.
  • Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, compared to $295.7 million as of December 31, 2025.

Guidance

  • The Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth quarter of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →